Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sjögren's Disease With Moderate to Severe Symptom Burden

NCT06440525 is registered in ClinicalTrials.gov with Resolve Therapeutics as lead sponsor.

NCT NCT06440525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sjögren's Disease With Moderate to Severe Symptom Burden
Lead sponsor
Resolve Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2024
Completion date
March 1, 2027
Enrollment
106 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren syndrome